tert-butyl 2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(phenoxymethyl)benzoate | 1204595-13-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: tert-butyl 2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(phenoxymethyl)benzoate
• CAS: 1204595-13-0
• 化学式: C₂₃H₂₆O₅
• 分子量: 382.456
• InChiKey: JHZANOCZABEGAB-BUHFOSPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.83
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(phenoxymethyl)benzoate 在 sodium tetrahydroborate 、 nickel(II) chloride hexahydrate 、 水 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 1.0h， 以100%的产率得到tert-butyl 2-(3-ethoxy-3-oxopropyl)-5-(phenoxymethyl)benzoate
  参考文献：
  名称：

  3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: Discovery and exploration of the carboxyamide side chain

  摘要：

  A series of 3-(2-aminocarbonyl-4-phenoxymethylphenyl) propanoic acid analogs were synthesized and evaluated for their EP3 antagonist activity in the presence of additive serum albumin. Several compounds were biologically evaluated for their in vivo efficacy with respect to the PGE(2)-induced uterine contraction in pregnant rats as well as their pharmacokinetics. The discovery process of these potent and selective EP3 antagonists and their structure activity relationship are also presented. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.11.023
• 作为产物：
  描述：

  tert-butyl 2-iodo-5-(phenoxymethyl)benzoate 、 丙烯酸乙酯 在 1,1'-双(二苯基膦)二茂铁 、 palladium diacetate 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 5.0h， 以69%的产率得到tert-butyl 2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-5-(phenoxymethyl)benzoate
  参考文献：
  名称：

  3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: Discovery and exploration of the carboxyamide side chain

  摘要：

  A series of 3-(2-aminocarbonyl-4-phenoxymethylphenyl) propanoic acid analogs were synthesized and evaluated for their EP3 antagonist activity in the presence of additive serum albumin. Several compounds were biologically evaluated for their in vivo efficacy with respect to the PGE(2)-induced uterine contraction in pregnant rats as well as their pharmacokinetics. The discovery process of these potent and selective EP3 antagonists and their structure activity relationship are also presented. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.11.023